Equillium, Inc. · NASDAQ:EQ
Equillium — Merger or Acquisition (December 2022)
7 slides from Equillium's merger presentation, Dec 6, 2022
Slide 1: Equillium & Ono Pharmaceutical Exclusive Option and Asset Purchase Agreement for Itolizumab
Equillium & Ono Pharmaceutical Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab 6 December 2022 Exhibit 99.2
Slide 2: Forward-looking statements
Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “co
Slide 3: Additional Information and Where to Find It
Additional Information Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed merger or otherwise. No offer of securities shall be
Slide 4: Ono Pharmaceutical: Option & Asset Purchase Agreement
Ono Pharmaceutical: Option & Asset Purchase Agreement Equillium receives upfront payment and full funding for itolizumab R&D in exchange for Ono exclusive option to purchase Equillium’s rights to itolizumab Option period expires three months following delivery of: topline data from the EQUALISE stud
Slide 5: Diversified Pipeline of First-In-Class Immunology Assets
Diversified Pipeline of First-In-Class Immunology Assets Drugs Indication & Delivery Pre-Clinical Phase 1 Phase 2 Phase 3 Partners Status & Designations EQ001 Itolizumab anti-CD6 acute graft-versus-host disease intravenous Pivotal study enrolling to support BLA FDA Fast Track and Orphan Drug Designa
Slide 6: Ono Pharmaceutical: Option & Key Takeaways
Operating cash runway into 2025 based on current plan Fully funds itolizumab development through option period and beyond current EQ101 & EQ102 studies Strong cash position: $44.5M 3Q22 ending cash + $26.0M upfront + $12.2M itolizumab R&D funding (3Q22 actual and 4Q22 & 1Q23 advances) Potential opti
Slide 7: Thank you
Thank you www.equilliumbio.com